title: Association Between Dosage Frequency and the Treatment Outcomes of Sildenafil in Young and Middle-aged Men With Erectile Dysfunction: A Chinese, Multicenter, Observational Study.
abstract: OBJECTIVE
  To evaluate the correlation between the dosage frequency of sildenafil and its treatment outcomes in men with erectile dysfunction (ED).
  
  
  METHODS
  Data were from a 4-week, multicenter, observational study of men (1699), between 18 and 60 years of age, with a clinical diagnosis of ED defined as the Sexual Health Inventory for Men (SHIM) score ≤21. The erectile function and quality of sexual life were evaluated at the baseline and the endpoint of sildenafil treatment (after 4 weeks) by using SHIM, Self-Esteem and Relationship Questionnaire, 36-Item Short Form Health Survey, Erection Hardness Score, and the global efficacy question.
  
  
  RESULTS
  Nine hundred thirty-five patients were enrolled in the ≤1 weekly, 573 in the 2-3 weekly, and 158 in the 4-7 weekly dosage frequency cohorts. After 4 weeks of treatment, a higher dosage frequency of sildenafil was associated with a better SHIM, Self-Esteem and Relationship Questionnaire, and 36-Item Short Form Health Survey score improvement (all P <.0001). Hyperlipidemia is a poor prognostic factor (odds ratio, 3.59; P = .04), whereas hypertension (odds ratio, 0.25; P <.01) and coronary heart disease (odds ratio, 0.56; P = .05) are sensitive to sildenafil treatment.
  
  
  CONCLUSIONS
  Higher dosage frequency of sildenafil is associated with a better improvement of sexual function and quality of life of men with ED, and the concomitant treatment of hyperlipidemia is recommended.
authors.affiliation: Reproductive Medical Center, First Hospital of Jilin University, Changchun, China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Yang
authors.affiliation: Reproductive Medical Center, First Hospital of Jilin University, Changchun, China.
authors.forename: Ruizhi
authors.initials: R
authors.lastname: Liu
authors.affiliation: Department of Urology, Peking University Third Hospital, Beijing, China. Electronic address: jianghui19640505@126.com.
authors.forename: Hui
authors.initials: H
authors.lastname: Jiang
authors.affiliation: Department of Urology, Peking University Third Hospital, Beijing, China.
authors.forename: Kai
authors.initials: K
authors.lastname: Hong
authors.affiliation: Department of Urology, Peking University Third Hospital, Beijing, China.
authors.forename: Lianming
authors.initials: L
authors.lastname: Zhao
authors.affiliation: Department of Urology, Peking University Third Hospital, Beijing, China.
authors.forename: Wenhao
authors.initials: W
authors.lastname: Tang
authors.affiliation: Department of Urology, Peking University Third Hospital, Beijing, China.
authors.forename: Jiaming
authors.initials: J
authors.lastname: Mao
mesh_terms: D000293:Adolescent; D000328:Adult; D006801:Humans; D008297:Male; D008875:Middle Aged; D055815:Young Adult; D002681:China; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D007172:Erectile Dysfunction / Q000188:drug therapy / Q000503:physiopathology; D017060:Patient Satisfaction; D010410:Penile Erection / Q000187:drug effects; D058986:Phosphodiesterase 5 Inhibitors / Q000008:administration & dosage; D010879:Piperazines / Q000008:administration & dosage; D011687:Purines / Q000008:administration & dosage; D011788:Quality of Life; D012725:Sexual Behavior; D000068677:Sildenafil Citrate; D013449:Sulfonamides / Q000008:administration & dosage; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D058986:Phosphodiesterase 5 Inhibitors; D010879:Piperazines; D011687:Purines; D000068677:Sildenafil Citrate; D013449:Sulfonamides